310 results
8-K
EX-99.1
KA
Kineta Inc
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; Kineta’s commercialization
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
and other company expenses of $1.1 million. Personnel costs increased due to higher salaries and benefits of $1.2 million from increased headcount … ; the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market
8-K
EX-99.1
6fbpfrk5 nq
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
EX-99.2
noml10fbrap503 s7qf
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
l98azd yz5nkboc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
1q4jq
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-10.1
iufmzyd3 jkueupmn9
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-10.2
8zunbryu6 taamo
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
EX-99.1
9yq52ky
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
EX-99.1
6wsvpbffhugo7itb
5 Jan 24
Regulation FD Disclosure
4:30pm
424B3
oxf ke0es04agij36p
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.1
f2j ts6486l7
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.2
z42a1c072t hb3mw4p
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-99.1
2ar68xr93o8yn7
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
l36ftt0cgz9f5cm74egh
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm